No injection of moxifloxacin

Phase 3Small molecule

UUniversity of Campinas, Brazil

No injection of moxifloxacin is one of 5 small molecule programs targeting Endophthalmitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndophthalmitisActive, not recruiting

EndophthalmitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Endophthalmitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

5 2

Cipro

Bayer

Phase 2

1 3

No injection of moxifloxacin

UUniversity of Campinas, Brazil

Phase 3

1 4

Levaquin

WWim Janssens

Preclinical

1 5

Ceftin

PPhiladelphia Eye Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endophthalmitis1 trial

Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.

Terminated·UUniversity of Campinas, Brazil·Phase 3·NCT02770729·3,640 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for No injection of moxifloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — No injection of moxifloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for No injection of moxifloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Campinas, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Campinas, Brazil

No injection of moxifloxacin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endophthalmitis1 trial

References

Drug Info

Quick Facts

Related News